Posted by Michael Wonder on 02 Jul 2021
Bevacizumab on the PBS
2 July 2021 - Mvasi, a biosimilar brand of bevacizumab, was listed on the PBS from 1 June 2021, as an unrestricted PBS benefit, which means all Australians who receive a prescription from their treating doctor for bevacizumab are able to access this medicine at the subsidised PBS price.
This follows the removal of the Avastin brand of bevacizumab, a biological medicine used to treat cancers, from the PBS on 1 June 2021 at the request of the pharmaceutical manufacturer, Roche.
